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Abstract
Since the identification of B‐cell translocation gene 1 (BTG1) and BTG2 as antiproliferation
genes more than two decades ago, their protein products have been implicated in a variety
of cellular processes including cell division, DNA repair, transcriptional regulation and
messenger RNA stability. In addition to affecting differentiation during development and in
the adult, BTG proteins play an important role in maintaining homeostasis under
conditions of cellular stress. Genomic profiling of B‐cell leukemia and lymphoma has put
BTG1 and BTG2 in the spotlight, since both genes are frequently deleted or mutated in
these malignancies, pointing towards a role as tumor suppressors. Moreover, in solid
tumors, reduced expression of BTG1 or BTG2 is often correlated with malignant cell
behavior and poor treatment outcome. Recent studies have uncovered novel roles for
BTG1 and BTG2 in genotoxic and integrated stress responses, as well as during
hematopoiesis. This review summarizes what is currently known about the roles of BTG1
and BTG2 in these and other cellular processes. In addition, we will highlight the molecular
mechanisms and biological consequences of BTG1 and BTG2 deregulation during cancer
progression and elaborate on the potential clinical implications of these findings.
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1 | INTRODUCTION
The B‐cell translocation gene (BTG)/TOB family of antiproliferation
proteins regulates cell‐cycle progression, apoptosis, and differentiation.
In particular, BTG1 and BTG2 have been identified as mediators of
genotoxic and cellular stress signaling pathways, promoting either cell
death or survival. Moreover, a role for BTG1 and BTG2 as tumor
suppressors in both lymphoid malignancies and solid tumors is
emerging. The capacity of BTG1 and BTG2 to protect cells from
oncogenic transformation relates to their ability to regulate gene
expression through association with transcriptional cofactors, but also
at the posttranscriptional level by controlling messenger RNA (mRNA)
stability. Furthermore, there is evidence that expression levels of BTG1
and BTG2 can be used as prognostic biomarkers in various cancers.
2 | THE STRUCTURE AND
TRANSCRIPTIONAL REGULATION
OF BTG PROTEINS
BTG1 was first identified as a translocation partner of the c‐MYC
gene in a case of B‐cell chronic lymphocytic leukemia (Rimokh
et al., 1991). Soon thereafter it was found that BTG1 expression
varied during cell‐cycle progression and that overexpression of its
gene product led to a cessation of growth, leading to the term
“antiproliferation gene” (Rouault et al., 1992). The highly related
BTG2 gene was discovered around the same time as a gene rapidly
induced by growth factors and mitogens (Bradbury, Possenti,
Shooter, & Tirone, 1991; Fletcher et al., 1991). A third member of
this family, TOB1 was identified a few years later, showing
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structural and functional similarities to BTG1. The subsequent
inclusion of three other proteins sharing a conserved core known
as AntiPROliferative (APRO) domain, as well as antiproliferative
properties, makes up what is currently known as the BTG/TOB
protein family. These six related proteins are known as BTG1,
BTG2/PC3/Tis21, BTG3/ANA, BTG4/PC3B, TOB1/TOB, and TOB2
(Winkler, 2010). The availability of crystal structures for BTG2 and
TOB1 confirms the presence of a structurally conserved region
within this protein family, harboring two motifs known as box A
and box B. A third motif, box C, is exclusively found in BTG1 and its
closest relative BTG2. The latter two genes, which are the focus of
this review, share 66% identity at the amino acid level; the only
substantial difference is the slightly longer C‐terminal region of
BTG1 (Rouault et al., 1992). Two LxxLL motifs, known to facilitate
protein–protein interactions, are located in the core region of
BTG1 and BTG2 (Figure 1).
The human BTG1 and BTG2 genes are located on chromosomes
12q22 and 1q32, respectively, and made up of only two exons
(Rimokh et al., 1991; Rouault et al., 1992, 1996). The resulting
transcripts and proteins encoded are highly unstable. Both BTG1
and BTG2 protein stability is regulated by the proteasome, which
involves ubiquitination by the SCF–βTrCP1 complex (Sasajima,
Nakagawa, Kashiwayanagi, & Yokosawa, 2012). BTG2 protein
stability is also controlled by the SCF–Skp2 complex (T. J. Park,
Kim, Park, Kim, & Lim, 2009). Moreover, BTG1 and BTG2 are
subject to other posttranslational modifications. For instance, both
proteins are phosphorylated at specific serine residues, allowing
interactions with other cellular effectors. It was shown recently that
mRNA expression of both BTG1 and BTG2 is subject to regulation by
microRNAs. For instance, c‐MYC can suppress BTG1 through miR‐
17–92 to maintain sustained proliferation and a neoplastic state in
lymphoma cells (Li, Choi, Casey, Dill, & Felsher, 2014). As many as
17 binding sites for miRNAs are found in the 3′ untranslated regions
of BTG2, suggesting a major role for these molecules in controlling
BTG2 transcript levels (Fei, Haffner, & Huttner, 2014).
BTG1 and BTG2 are present both in the nucleus and the
cytoplasm, and it has been suggested that the cellular trafficking of
both proteins influences their activities (Kawakubo et al., 2006;
Rodier et al., 2001). Overall, the COOH‐terminal region regulates
nuclear localization, while the NH2‐terminal part is required for
cytoplasmic retention. Although both genes are broadly expressed,
the BTG1 expression is most abundant in the pancreas, heart, and
hematopoietic tissues, while high levels of BTG2 are detected in
various organs including kidney, lung, prostate, pancreas, thymus,
central nervous system, and skeletal muscle. Consistent with their
antiproliferative role, expression appears to be highest in quiescent
cells, and downregulated when cells progress towards the G1–S
transition (Rouault et al., 1992, 1996).
BTG2 was originally identified as a p53‐inducible gene. Expres-
sion of BTG2 is significantly increased in response to DNA damage,
and this increase is a consequence of p53 induction since the
expression of a loss‐of‐function p53 mutant does not lead to BTG2
accumulation in this context (Rouault et al., 1992). BTG2 was also
shown to be sensitive to nuclear factor‐κB (NF‐κB) activation. The
BTG2 expression is induced by a variety of genotoxic agents (ionizing
radiation, UV, adriamycin), growth factors, estrogen, serum, tetra-
decanoylphorbol acetate, interleukin 6, and cyclic adenosine mono-
phosphate (cAMP). BTG1 is also DNA damage‐inducible gene, but
unlike BTG2, BTG1 induction appears to be independent of p53
(Cortes et al., 2000). BTG1 transcript levels are elevated in response
to glucocorticoid exposure, 4‐hydroxytamoxifen, triiodothyronine
(T3), transforming growth factor β (TGF‐β), serum and angiogenic
growth factors. Hence, BTG1 and BTG2 are subject to regulation by a
variety of steroid hormone receptors and growth factor pathways.
3 | BTG1 and BTG2 FUNCTION AS GLOBAL
REGULATORS OF GENE EXPRESSION
3.1 | Regulation of gene transcription
Both BTG1 and BTG2 function as transcriptional coactivators that
associate with various cellular targets. For instance, both proteins can
bind to and positively modulate the activity of HoxB9, a member of
Hox gene family of transcription factors, critical determinants of
pattern formation during metazoan development (Prevot et al., 2000).
Moreover, the two conserved LxxLL motifs found in both BTG1 and
BTG2 allow interaction with and modulation of various nuclear
receptors, including T3 receptor, all‐trans retinoic acid (RA) receptor,
estrogen receptor α (ERα) and androgen receptor (Busson et al., 2005;
Hu et al., 2011; Prevot et al., 2001). The box C domain, exclusively
present in BTG1 and BTG2 (Figure 1), facilitates binding to protein
arginine methyltransferase I (PRMT1; Lin, Gary, Yang, Clarke, &
Herschman, 1996). Members of this enzyme family catalyze arginine
methylation on both histone and nonhistone proteins. This type of
posttranslational modification, which is abundantly found in mamma-
lian tissues, has been implicated in various biological processes (e.g.,
signaling events, transcription, mRNA biogenesis) and can become
deregulated in cancer cells (Bedford & Clarke, 2009). PRMT1 is the
F IGURE 1 Domains and interaction partners of BTG1 and BTG2.
The conserved core of BTG1 and BTG2, known as the APRO domain,
contains three smaller motifs, known as box A, box B, and box C. These
boxes facilitate interactions with various protein partners. An additional
LxxLL motif, which is required for binding to nuclear receptors, is also
found in BTG1 and BTG2. BTG: B‐cell translocation gene; CAF1,
CCR4‐associated factor 1; PRMT1, protein arginine methyltransferase I
[Color figure can be viewed at wileyonlinelibrary.com]
5380 | YUNIATI ET AL.
primary enzyme mediating asymmetric dimethylarginine methylation.
One of the most well‐studied biological roles for PRMT1‐mediated
arginine methylation is to coactivate transcription. Consistent with
these findings, BTG2, together with PRMT1, enhances RA transcrip-
tion activity and RA‐induced differentiation (Passeri et al., 2006), while
we have demonstrated that the BTG1–PRMT1 complex positively
regulates glucocorticoid receptor (GR) signaling in leukemic cells (van
Galen et al., 2010). Similarly, BTG1 was found to improve insulin
sensitivity by promoting RAR activation and, eventually, c‐Jun‐
mediated transcription (Xiao et al., 2015), which adds to the previously
reported role of BTG1 as an enhancer of c‐Jun transcriptional activity
during muscle development (Busson et al., 2005).
3.2 | Posttranscriptional regulation
In addition to their involvement in transcriptional regulation, BTG
family members affect gene expression by controlling mRNA
abundance. Both BTG1 and BTG2 were shown to bind to the Ccr4‐
associated factor 1 (CAF1) subunit of the multisubunit CCR4–NOT
complex. This deadenylase complex promotes mRNA degradation by
shortening/removal of the poly(A) tail (Mauxion, Faux, & Seraphin,
2008; Rouault et al., 1998). BTG2, through its interaction with CAF1
and CCR4, enhances mRNA deadenylation and consequently mRNA
decay (Mauxion et al., 2008). More specifically, BTG2 binds to the
poly(A)‐binding protein PABPC1 to stimulate CAF1 deadenylase
activity, thus directly controlling poly(A) tail length (Stupfler, Birck,
Seraphin, & Mauxion, 2016). The CNOT7 and CNOT8 deadenylase
subunits of the CCR4–NOT complex are also bound by BTG proteins,
affecting mRNA turnover of several genes, although the exact
mechanism is unknown (Aslam, Mittal, Koch, Andrau, & Winkler,
2009). In addition, BTG2 expression, under the coordination of the
microRNA miR‐132, represses the translation of specific circadian
clock‐related proteins by enhancing their mRNA decay (Alvarez‐
Saavedra et al., 2011).
The functional consequences of BTG1/2‐induced deadenylation
in vivo remain incompletely understood. Since the poly(A) tail not
only maintains mRNA stability but also regulates protein translation,
changes in poly(A) tail length could also lead to a block in protein
translation. It is presently unclear to what extent control of
deadenylation contributes to the various cell biological processes
affected by BTG1 or BTG2.
4 | BIOLOGICAL PROCESSES REGULATED
BY BTG PROTEINS
Both BTG1 and BTG2 act as effectors of signaling pathways that take
part in the regulation of key cellular processes, such as differentia-
tion and apoptosis. BTG1 and BTG2 are both negative regulators of
the cell cycle, and in some cell types, their overexpression can lead to
cell death. Next to this, BTG1 and BTG2 expression are required for
the differentiation of neuronal cells, the proliferation of myoblasts,
development of vertebral patterning, and maintenance of hemato-
poietic progenitor cells. Cellular response to genotoxic stress
requires BTG2, which acts in response to p53 activation. BTG1 is a
novel component of the ISR, positively regulating activating
transcription factor 4 (ATF4)‐mediated transcriptional activity in
response to cellular stress conditions. The major biological processes
affected by BTG1 and BTG2 function are summarized in Figure 2.
4.1 | Regulation of cell cycle and apoptosis
The first evidence linking BTG1 to the control of cell growth and
division came from the observation that its transcript levels peak in
the G0/G1 phase of cell cycle and decrease dramatically during the
G1/S phase transition (Rouault et al., 1992). Consistent with this
notion, overexpression of BTG1 generally suppresses cell growth.
However, how BTG1 expression contributes to the tightly controlled
cell‐cycle transition remains to be elucidated. More is known about
the role of BTG2 during cell‐cycle progression. Similar to BTG1, BTG2
mRNA levels are highest in quiescent cells, and forced expression of
this gene leads to suppression of growth (I. K. Lim et al., 1998;
Montagnoli, Guardavaccaro, Starace, & Tirone, 1996). Synchroniza-
tion experiments revealed that the antiproliferative effect of BTG2
F IGURE 2 Major biological processes regulated by BTG1 and
BTG2. Five major biological processes regulated by BTG1 and BTG2.
Cell cycle: BTG1 and BTG2 expression induce cell cycle arrest at the
G1 stage. BTG2 also facilitates DNA damage‐induced G2/M arrest.
Differentiation: BTG1 and BTG2 expression are crucial for the
differentiation of various tissues such as neurons and axial skeleton.
Genotoxic stress: DNA damage can lead to programmed cell death
via BTG1 and BTG2, in‐or dependent of p53. Integrated stress
response: BTG1, together with PRMT1, promotes ATF4‐mediated
cellular stress adaptation. BTG2 is a downstream effector of ROS
and NF‐κB to overcome oxidative stress. Hematopoiesis: BTG1 acts
as downstream effector of HLX, FOXO3a, and PAX5 to regulate the
differentiation of hematopoietic, erythroid and B‐cells progenitors,
respectively. BTG2 is involved in the differentiation of B cells and
thymocyte progenitors. ATF4: activating transcription factor 4;
BTG: B‐cell translocation gene; HLX: H2.0‐like homeobox;
NF‐κB: nuclear factor‐κB; ROS: reactive oxygen species [Color figure
can be viewed at wileyonlinelibrary.com]
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involves downregulation of cyclin D1, leading to the inhibition of
retinoblastoma (Rb) phosphorylation and G1 arrest (Guardavaccaro
et al., 2000; Montagnoli et al., 1996). This suppression of cyclin D1
levels was recently shown to be dependent on the binding between
BTG2 and histone deacetylases HDAC1, HDAC4, and HDAC9
(Micheli, D'Andrea, Leonardi, & Tirone, 2016). In the absence of
functional Rb, BTG2 prevents G1 to the S phase progression by
reducing the level of cyclin E and cyclin‐dependent kinase (cdk) 4
(I. K. Lim et al., 1998). More specifically, recent work showed that in
B cells, cdk4 is a direct target of the BTG2–PRMT1 complex and that
its methylation results in degradation of the protein (Dolezal
et al., 2017).
Moreover, BTG2 is capable of inducing a G2/M arrest in a p53‐
independent manner. BTG2 expression appears to be sufficient to
induce cellular senescence in normal fibroblasts by antagonizing the
cell‐cycle regulator Pin1 (Wheaton, Muir, Ma, & Benchimol, 2010). In
human tumor cell lines, one feature of drug‐induced cellular
senescence is upregulation of BTG1 and BTG2, with no or limited
dependence on p53 expression (Chang et al., 2002). Finally, four
members of the B‐cell translocation gene family (BTG1, BTG2, BTG3,
and TOB1) were found to be regulated by the tumor suppressor
p19(Arf), in a p53‐independent manner, leading to cell‐cycle arrest
(Kuo et al., 2003).
Of note, BTG1 and BTG2 expression may not only lead to
induction of cell‐cycle arrest but may also be involved in the control
of apoptosis. Forced expression of BTG1 leads to increased cell death
in several cell types including murine fibroblasts, microglia, and
human breast cancer cells. In the brain, upregulation of BTG1
sensitizes microglial cells to inflammatory‐induced death (Lee et al.,
2003). In breast tissue, apoptosis, induced by suppression of the
antiapoptotic protein BCL2, requires expression of BTG1 (Nahta
et al., 2006), while in atherosclerotic lesions, BTG1 expression
localizes to macrophage‐rich areas as well as apoptotic cells (Corjay,
Kearney, Munzer, Diamond, & Stoltenborg, 1998).
4.2 | Cellular differentiation
Owing to their roles in controlling cell growth through regulation of
cell‐cycle transition or arrest, both BTG1 and BTG2 exert unique
functions during differentiation and maintenance of certain tissues.
For instance, BTG1 expression appears to be required for the
maintenance of stem and progenitor cells in the brain. In mice lacking
Btg1 expression, the proliferating dentate gyrus stem and progenitor
cells decreased significantly by number and underwent apoptosis.
This phenomenon was observed in both young and adult Btg1‐null
mice. Taken together, loss of BTG1 negatively affects the prolifera-
tion and induces apoptosis of these cells in the dentate gyrus and
subventricular zone (Farioli‐Vecchioli, Micheli, et al., 2012). BTG2
plays a role in the neurogenesis during adulthood; its expression level
is induced during neurogenesis and inhibition of expression leads to
the programmed death of differentiated neurons in vitro (el‐Ghissassi
et al., 2002). In vivo, mice deficient for Btg2 show an accumulation of
undifferentiated neurons and impaired contextual memory. This may
be the consequence of Btg2 being the negative regulator of Id3, an
inhibitor of proneural gene activity (Farioli‐Vecchioli et al., 2009).
How BTG proteins impinge on neuronal developments remains
poorly understood. One study suggests that BTG2, together with the
arginine methyltransferase PRMT1, controls neurite outgrowth by
regulating arginine methylation in the nucleus (Miyata, Mori, &
Tohyama, 2008). In differentiated neuronal cells, BTG2 is critical for
neuroprotection as an effector of the transcription factor cAMP‐
response element binding protein (CREB; Tan, Zhang, Hoffmann, &
Bading, 2012). In addition, BTG1 was shown to be involved in
differentiation and proliferation of myoblasts, endothelial cells,
sperm cells and ovary cells. BTG2 also participates in myoblast
proliferation and differentiation by regulating cyclin D1 levels
(Evangelisti et al., 2009). BTG2 expression, under control of Stat3
signaling, also regulates adipocyte differentiation (S. Kim, Hong, &
Park, 2016).
In vivo, Btg2 transcript levels are regulated during pregnancy,
lactation and involution in the rat mammary gland (Kawakubo et al.,
2004), consistent with a role in proliferative control during mammary
gland development. Moreover, studies using Btg2 knockout mice
revealed that Btg2 expression is indispensable for the development
of the axial vertebrae since these mice exhibited abnormal vertebral
patterns. As Btg2 was also found to be a positive regulator of the
bone morphogenetic protein (BMP) signaling pathway, this vertebral
transformation in Btg2‐null mice was proposed to be a consequence
of attenuated BMP signaling (S. Park et al., 2004). We recently
demonstrated, using Btg1 knockout mice, that Btg1 expression also
contributes to the normal vertebral patterning of the axial skeleton.
Deletion of Btg1 gene resulted in the partial posterior transformation
of the seventh cervical vertebra, and this defect is enhanced by losing
both Btg1 and Btg2. Btg2‐deficient mice also showed impaired
development in the thoracic–lumbar region of the axial skeleton
and exhibited posterior homeotic transformation at the thoracic–
lumbar junction, which was not observed in Btg1‐deficient mice. In
conclusion, while loss of Btg2 has more pronounced effects on
posterior transformation, Btg1 fulfills both unique and synergistic
roles in maintaining the identity of the axial skeleton (Tijchon
et al., 2015).
4.3 | Hematopoiesis
The development and maintenance of hematopoietic stem cells
(HSCs) is tightly controlled by a hierarchy of transcription factors,
which are subject to regulation by complex signaling cascades. HSCs
are defined by their predominantly quiescent state, their capacity to
generate lineage‐committed progenitors, and their ability to be
“active” and self‐renew in response to stress insults, such as
chemotherapy intervention. During stress‐induced activation of
HSCs, the BTG1 expression is required to return from a proliferative
state back into quiescence (Venezia et al., 2004). Furthermore, BTG1
is among the downstream effectors of nonclustered H2.0‐like
homeobox (HLX), which acts as an important regulator of early
hematopoiesis (Kawahara et al., 2012). Next, to its role in HSCs,
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BTG1 expression was found to regulate the expansion and
differentiation of erythroid progenitor cells downstream of the
transcription factor FOXO3a (Bakker et al., 2004).
BTG2 is also involved in both proliferation and differentiation of
hematopoietic cells. During the course of thymocyte development,
the BTG2 expression is high in quiescent thymocytes while
expression decreases in proliferating progenitors, suggesting that
the presence of BTG2 allows thymocytes to remain in a nondividing
state (Konrad & Zuniga‐Pflucker, 2005). Similarly, BTG2 expression
in mature T cells inhibits cell proliferation and survival (Ryu et al.,
2014). BTG2 was also shown to negatively affect the expansion of
HSCs in the bone marrow upon estradiol stimulation, by inhibiting
the mammalian target of rapamycin (mTOR) pathway (B. C. Kim, Ryu,
Oh, & Lim, 2008). Moreover, BTG2 favors RA‐induced hematopoietic
differentiation through regulation of gene‐specific histone methyla-
tion, by recruiting the arginine methyltransferase PRMT1 to the RA
receptor complex (Passeri et al., 2006).
An additional function for BTG1 and BTG2 in hematopoiesis was
revealed with the identification of BTG1 as a target of PAX5, a
transcription factor that dictates the commitment of lymphoid
progenitor cells to the B‐cell lineage (Schebesta et al., 2007).
Moreover, BTG2 regulates pre‐B‐cell differentiation through
PRMT1‐mediated methylation of CDK4, thus inducing cell‐cycle
arrest to limit pre‐B‐cell expansion (Dolezal et al., 2017). In search of
a functional role for BTG1 and its closely related family member
BTG2 during B lymphopoiesis, we used knockout mice to study the
fate of hematopoietic progenitor cells upon loss of these genes.
Whereas the absence of Btg1 and Btg2 reduces the number of B‐
progenitor cells in bone marrow and spleen, we demonstrated that
both genes fulfill a unique role during the distinct stages of B‐cell
development: loss of Btg2 affects the propagation of early progenitor
cells (pre–pro, pro‐B and pre‐B cells), while Btg1 deficiency leads to
deregulation of later stages of B‐lineage differentiation, including the
immature B cells (Tijchon et al., 2016). In fact, Btg1 acts as a positive
regulator of B‐cell progenitor outgrowth in response to IL‐7 using in
vitro colony assays (Tijchon et al., 2016). Thus, depending on the cell
lineage context, BTG1 and BTG2 can either enhance or inhibit cell
proliferation.
4.4 | Regulation of genotoxic stress response
BTG2 is required for DNA damage‐induced G2/M arrest, as the
disruption of BTG2 alters cellular response to DNA damaging agents
(Rouault et al., 1992). In Hela cells, doxorubicin‐induced cell death is
mediated by BTG2, which appears to involve the accumulation of
H2O2 (Y. B. Lim, Park, & Lim, 2008). Conversely, BTG2 was shown to
suppress apoptosis and promote DNA repair during DNA damage in
response to p53 activation, suggesting that the apoptosis‐inducing
effects of BTG proteins are context dependent (K. S. Choi
et al., 2012).
Furthermore, BTG2 was identified as one of the genes upregu-
lated in response to activation of p53, while the the loss of BTG2
expression cooperates with oncogenic Ras in the transformation of
primary cells (Boiko et al., 2006). The tumor suppressor p53 and the
proto‐oncogene Ras are among the most frequently mutated genes in
human malignancies, and the cooperation between both regulatory
networks to induce cellular transformation is well established. In
primary fibroblasts, suppression of BTG2 mimics loss of p53 function
in collaboration with oncogenic Ras (H‐Rasv12), allowing cells to
bypass replicative senescence while triggering transformation and
immortalization. Repression of BTG2 in this oncogenic setting raises
the level of cyclins D1 and E1 and phosphorylation of Rb, which is in
line with previous reports (Guardavaccaro et al., 2000; I. K. Lim et al.,
1998). Further studies have identified additional crosstalk between
the p53–BTG2 axis and oncogenic Ras, where BTG2, in the context of
p53 deregulation, is capable of binding to H‐Rasv12 and repress its
activity, while the perturbed function of BTG2 leads to elevated H‐
Ras activity (Buganim et al., 2010). Recently, BTG2 was shown to
regulate p53 activity via posttranslational modification. This BTG2‐
mediated p53 regulation leads to a switch from senescence to
apoptosis, which reduces tumorigenicity in bladder cancer cells
expressing oncogenic Ras and mutant p53 (O. R. Choi, Ryu, & Lim,
2016). Altogether, these findings establish BTG2 as a tumor
suppressor and show that its downregulation, as it is frequently
observed in solid tumors, may synergize with oncogenic signals, such
as Ras, to induce malignant transformation.
4.5 | A role for BTG1 and BTG2 in the integrated
stress responses (ISRs)
In the developing organism as well as in the adult, cells are exposed
to a variety of stressors. These include extrinsic cell factors such as
hypoxia or nutrient starvation, but also cell intrinsic stresses such as
viral infections, oncogene activation or endoplasmic reticulum (ER)
stress, which is the result of an accumulation of misfolded proteins in
the ER. To optimally respond to these challenges and restore cellular
homeostasis, eukaryotic cells have evolved an adaptive cellular
mechanism known as the ISR. Activation of the ISR leads to a
shutdown of global protein synthesis, which requires phosphoryla-
tion of eurkaryotic translation initiation factor 2 (EIF2α) by one of
four stress‐activated kinases, which are selectively sensitive to either
amino acid starvation, hypoxia, viral infection or protein misfolding.
At the same time, however, translation of a select set of target genes,
such as that of ATF4 is enhanced. Since ATF4 controls the expression
of genes involved in amino acid transport and metabolism, protection
from oxidative stress and protein homeostasis, increased expression
or activation of ATF4 usually acts to promote cell survival and
restore cellular homeostasis. However, under conditions of severe or
sustained stress, activation of ATF4 may lead to the opposite effect,
that is, the execution of apoptosis. As the expression of BTG1 and
BTG2 are induced by a variety of stress stimuli that activate the ISR,
we studied a potential role for BTG1 and BTG2 in ATF4‐mediated
stress signaling. By exposing cells deficient for Btg1 or Btg2 to
stressors that activate ATF4, it was observed that BTG1, but not
BTG2, positively regulates ATF4‐mediated transcriptional activity.
Moreover, we demonstrated that BTG1 physically interacts with
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ATF4, to modulate its activity by recruitment of the arginine
methyltransferase PRMT1. Indeed, ATF4 is methylated by PRMT1
on several arginine residues, while the loss of ATF4 methylation
appears to selectively reduce expression of ATF4 target genes
implicated in apoptosis induction and stress‐induced growth arrest
(Yuniati et al., 2016). As a consequence, cells deficient for BTG1 show
increased cell survival under conditions of sustained cellular stress.
Although these experiments point to a role for BTG1 as a
transcriptional coregulator in the control of cellular stress responses,
we cannot rule out that additional effects on stress signaling may
involve posttranscriptional regulation by the Ccr4–Not complex. As
for BTG2, the observation that its expression, in addition to its role in
(p53 dependent) genotoxic stress, can also be induced by oxidative
stress suggests different roles for this protein in cellular adaptation
to stress. In response to stress challenges, such as serum deprivation
and oxidative stress, the BTG2 expression is strongly upregulated as
a consequence of the generation of reactive oxygen species (ROS)
and subsequent activation of ΝF‐κΒ (Imran & Lim, 2013). ΝF‐κΒ
signaling is not only central to inflammation and immunity, but also
plays a role in oxidative stress through its crosstalk with ROS
(Morgan & Liu, 2011). In this context, BTG2 may act as a downstream
effector of ΝF‐κΒ in response to cellular stress.
5 | BTG PROTEINS IN CANCER
5.1 | Deregulated expression of BTG1 and BTG2 in
solid tumors
Given the important roles of BTG1 and BTG2 in fundamental
biological processes such as proliferation, differentiation, and cellular
stress responses, it is not surprising that aberrations in expression or
function of these proteins are observed in various malignancies.
Deregulated expression of BTG1 or BTG2 is seen in a variety of solid
tumors. In some of these cases decreased BTG1 expression appears
to correlate with poor overall survival and tumor metastasis
formation. The studies in gastric and hepatocellular carcinoma found
no evidence for promoter hypermethylation or gene mutations as the
causative factor for BTG1 downregulation (Kanda, Oya, et al., 2015;
Kanda, Sugimoto, et al., 2015). However, BTG1 downregulation in
ovarian carcinoma cell lines does appear to involve promoter
methylation (J. Y. Kim, Do, Bae, & Kim, 2017). Overall, the early
genetic event(s) that contribute to BTG1 loss in these solid
malignancies are still largely unknown and remain to be determined.
In other solid tumor models, where BTG1 is subject to
posttranscriptional silencing by microRNAs, low BTG1 levels appear
to be disadvantageous for cells. For instance, in colorectal carcinoma,
BTG1 was identified as a direct target of miR‐22, a class of miRNA
controlling the switch between autophagy and apoptosis in response
the chemotherapeutic agent 5‐FU (H. Zhang et al., 2015). The
authors demonstrated that high levels of miR‐22 coincided with
decreased BTG1 expression, which rendered these colorectal cancer
cells more sensitive to therapy. Likewise, downregulation of BTG1 by
miR‐454‐3p appears to increase sensitivity to irradiation in renal
carcinoma cells by promoting cell death (Wu et al., 2014). On the
other hand, overexpression of miR‐511 in human hepatoma cells and
miR‐301A in colon cancer cells inhibits the expression of BTG1 and
promotes tumor cell proliferation (He et al., 2017; S. Zhang et al.,
2017). These studies not only reveal additional regulatory mechan-
ism controlling BTG1 transcript levels but also suggest that the
effects on cancer progression or response to therapy are highly cell
and context dependent.
The role of BTG2 during tumor progression seems to be more
unambigious. In breast carcinoma, BTG2 downregulation, through an
unknown mechanism, leads to increased cyclin D1 expression and
elevated AKT phosphorylation. Low level of BTG2 in breast tumor
thus correlates with increased tumor grade, disease progression and
decreased overall survival (Kawakubo et al., 2004, 2006; Takahashi
et al., 2011; van de Vijver et al., 2002). An elevated amount of cyclin
D1/cyclin E in liver cancer is a consequence of the low level of BTG2,
leading to increased tumor grade (Z. Zhang et al., 2011). In prostate
cancer, BTG2 is a target of miR‐32, miR‐21, and its suppression
results in disease initiation and progression, therapy resistance, and
metastasis (Coppola et al., 2013; Jalava et al., 2012). These findings
point to a predominantly tumor suppressive function for BTG2. In
vivo studies using knockout and overexpression of Btg2 in mice
confirm a role for this gene as a tumor suppressor in medulloblas-
toma (Farioli‐Vecchioli et al., 2007; Farioli‐Vecchioli, Cina,
et al., 2012).
5.2 | BTG1 and BTG2 are frequently affected by
gene deletions and mutations in B‐cell malignancies
In the past decade, genome‐wide profiling studies revealed that
genetic aberrations in BTG1 and BTG2 are frequently observed in B‐
cell malignancies. Somatic missense mutations affecting either BTG1
or BTG2 are relatively common in diffuse large B‐cell lymphoma
(DLBCL; Lohr et al., 2012; Morin et al., 2011; Reddy et al., 2017),
while point mutations in BTG1 and BTG2 were also identified in
follicular lymphoma (FL), a histologically low‐grade lymphoma
(Pasqualucci et al., 2014). Of note, in the ABC subtype of DLBCL,
genetic alterations in BTG1 are associated with poor survival, while
in FL, mutations in BTG1 appear to be correlated with disease
progression (Kridel et al., 2016; Reddy et al., 2017). In Burkitt
lymphoma (BL) subtype with RBL2/p130 mutation, the BTG1
expression is suppressed, resulting in loss of growth control (De
Falco et al., 2007). Finally, BTG1 copy number alterations are
detected with a high frequency in lymphoplasmacytic lymphoma
cases, leading to speculation that BTG1 loss may contribute to the
pathogenesis of this non‐Hodgkin lymphoma subtype (Hunter et al.,
2014). The mutations that are found in lymphomas most likely arise
from erroneous somatic hypermutation (SHM) events. During B‐cell
development, SHM, which is orchestrated by activation‐induced
deaminase (AID), promotes antibody diversity and maturation. Off‐
target AID activity, however, can also lead to mutations in adjacent
oncogenes or tumor suppressors and contribute to lymphomagen-
esis. SHM‐associated mutation hotspots have been mapped closely to
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the regulatory region of BTG2 and consequently may also be
responsible for the introduction of mutations in this gene (Jiang,
Soong, Wang, Melnick, & Elemento, 2012). Recent studies have shed
new light on the role of BTG1 in lymphoma pathogenesis. By
combining in vitro and in vivo studies, Li et al. (2014) demonstrated
that MYC maintains a neoplastic state by suppression of four
chromatin regulatory genes, one of which is BTG1. Suppression of
these MYC effector genes involves upregulation of miR‐17–92.
Knockdown of BTG1 alone was shown to be sufficient to (partly)
overcome proliferation arrest in response to MYC inactivation,
suggesting that suppression of BTG1, together with these other miR‐
17–92 targets, is required for MYC‐induced transformation and
lymphomagenesis. Taken together, BTG1 appears to act as a negative
regulator of proliferation and a tumor suppressor in lymphoma.
In B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), the
most common type of cancer in children, microdeletions affecting
BTG1, but not BTG2, are recurrently detected. Single copy losses
affecting this gene occur at a frequency of around 9%, while BTG1
copy number losses appear to be enriched in specific cytogenetic
subgroups, such as ETV6‐RUNX1, BCR‐ABL1, and BCR‐ABL1‐like
positive BCP‐ALL, and co‐occur with genetic alterations affecting
the B‐lineage determinants IKZF1 and PAX5 and the immune
modulatory molecule BTLA (Kuiper et al., 2007; Mullighan et al.,
2007; Roberts et al., 2014). We recently demonstrated that BTG1
deletions arise as the result of off‐target V(D)J recombination, which
takes place during pre‐B‐cell expansion to create a diverse repertoire
of antigen receptor specific B and T cells (Waanders et al., 2012).
Moreover, we observed that unique BTG1 deletions can arise
independently in multiple subclones, which either remain present
as minor populations or develop into predominant clones. Interest-
ingly, different leukemic blast populations lacking BTG1 can be found
as subclones during diagnosis and at relapse, confirming that BTG1
deletions occur repeatedly during disease progression (Mullighan
et al., 2008; Waanders et al., 2012).
Although the origin and nature of BTG1 aberrations in BCP‐ALL
have been elucidated, how BTG1 deregulation contributes to
leukemogenesis is still not well understood. The presence of BTG1
deletions at diagnosis suggests that loss of BTG1 most probably acts
as a cooperating event during leukemic transformation (Moorman
et al., 2012; Moorman et al., 2014). Indeed, we recently showed that
in a mouse model, loss of Btg1 cooperates with deletions of the tumor
suppressor Ikfz1 to promote leukemia development. Disease in-
cidence increases while time‐to‐leukemia is shortened when either
one or both copies of the Btg1 gene are deleted (Scheijen et al.,
2016). Furthermore, recent analysis looking at the co‐occurrence of
BTG1 deletion with specific genetic alterations has linked BTG1 loss
to the incidence of relapse. For instance, BTG1 deletions predict a
poor outcome in selected genetic subtypes of BCP‐ALL (Scheijen
et al., 2016). In an independent cohort of relapsed pediatric BCP‐ALL,
BTG1 deletions were associated with induction failure/death and
second relapse, specifically in high‐risk group patients. The combina-
tion of BTG1 and deletions affecting NR3C1, which encodes the GR,
appeared to be mutually exclusive and further increased the risk of
death (Irving et al., 2016). Both of these studies are in line with our
previous observations showing that loss of BTG1 confers resistance
to synthetic glucocorticoids in cell culture models by modulating GR‐
mediated gene expression (van Galen et al., 2010).
6 | BTG1 AND BTG2 AS TUMOR
SUPPRESSORS: CLINICAL IMPLICATIONS
A number of observations point to a tumor suppressive role for BTG1
and BTG2 in a range of malignancies, although in most examples, the
exact mechanism by which BTG1 or BTG2 contribute to tumor
development/progression requires further investigation. The fact
that in solid tumors reduced expression of BTG1 or BTG2 associates
with poor outcome suggests that the expression of their gene
products could serve as biomarkers for disease progression. For
example, BTG1 expression levels can be used to monitor the
remission status of acute myeloid leukemia patients and the
progression of proximal nondiffuse and diffuse gastric cancer
patients (Cho et al., 2004; Kanda, Oya, et al., 2015). In addition, the
finding that BTG1 deletions are enriched in distinct high‐risk ALL
subgroups, such as BCR‐ABL1, and BCR‐ABL1‐like ALL, and are
correlated with poor outcome in IKZF1‐deleted ALL (Scheijen et al.,
2016), requires further investigation to carefully examine the specific
contribution of BTG1 copy number losses to disease progression in
these ALL subtypes.
In breast and prostate carcinomas, where BTG2 expression was
found to be reduced, therapies restoring BTG2 expression may
contribute to the inhibition of cancer cell proliferation. Examples of
such interventions include the ErbB/HER inhibitor lapatinib in breast
tumors, the therapeutic radionuclide iodine‐131 in thyroid cancer
cells, and the chemotherapy drug cisplatin, the cell‐cycle inhibitor L‐
mimosine, and the topoisomerase inhibitors camptothecin and
doxorubicin in prostate carcinoma cells (Chiang, Tsui, Chung, Yeh,
Chang, et al., 2014; Chiang, Tsui, Chung, Yeh, Feng, et al., 2014;
Chung et al., 2012; Takahashi et al., 2011; Zhao & Pang, 2017).
Moreover, BTG2 is also among a set of genes whose expression
pattern can be used as a biomarker to predict the recurrence of
prostate cancer (Long et al., 2014).
7 | CONCLUSIONS AND PERSPECTIVES
BTG1 and BTG2 are highly versatile proteins that exhibit both
unique and redundant roles in growth control, differentiation and the
regulation of apoptosis. Moreover, both proteins are involved in
metabolic regulation and adaptation to cellular stress. While
deregulation of BTG1 and BTG2 is observed in a variety of
malignancies and often associated with an unfavorable prognosis,
their complex roles during malignant transformation and disease
progression require further investigation. Also with respect to their
molecular functions, a number of questions remain unanswered.
While some studies emphasize the role of these proteins as
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regulators of mRNA deadenylation, affecting mRNA stability or even
protein translation, BTG proteins also function as transcriptional
coregulators, affecting arginine methylation of transcription factors
and histone proteins. In this respect, the association of PRTM1 with
BTG1 or BTG2 will promote the methylation of specific subsets of
target proteins. PRMT1 has many substrates, which explains why
loss‐of‐function studies have shown profound, yet tissue‐specific and
heterogenous effects (Bedford & Clarke, 2009). It frequently remains
unclear which substrate is responsible for a specific phenotype that
can be found in studies of PRMT1 deficiency. As discussed above,
loss of BTG1 or BTG2 can be associated with the promotion of tumor
growth. At least part of this phenotype may be attributable to the
loss of PRMT1‐mediated methylation of specific substrates. This is
why it is important to study PRMT1 function in complex with
cofactors and their substrates.
The fact that BTG proteins are upregulated in response to a
broad variety of cellular stressors, growth factors, and steroid
hormones, suggest a central role in maintaining cellular homeostasis.
However, an overarching mechanism has yet to be identified. A
comprehensive understanding of how downregulation/inactivation of
these versatile proteins affects tumor progression or response to
therapy may ultimately contribute to the design of novel and more
effective anticancer therapies.
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